FDA Approves IsoPSA as an Adjunct Test for Prostate Cancer Diagnosis, Potentially Reducing the Need for Biopsy

2025.12.15

Rare Disease Diagnosis Shifts from Single-Gene Testing to the NGS Era

2025.12.09

Automated Mass Spectrometry System Receives FDA 510(k) Clearance, with Plans for Introduction in Korea

2025.11.17

Dow Biomedica and 10x Genomics Spotlight the Future of Precision Cell Therapy at KSGCT 2025

2025.11.10

Unveiling a Technology for Early Prediction of Multiple Myeloma Relapse

2025.11.04

Early Prediction of Colorectal Cancer Recurrence Through a Blood Test

2025.07.30

Shield Blood Test Added to U.S. NCCN Guidelines as Korean Launch Nears

2025.07.15

NGS to Reduce Infectious Disease Diagnosis from 33 Days to 3 — Clinical Application Imminent

2025.07.01

Lung Cancer Monitoring with CTC Liquid Biopsy: Dow Biomedica Highlights Innovative Technology"

2025.06.25

Dow Biomedica Introduces ‘Shield’ Colorectal Cancer Screening Test to Korean Market

2025.06.17

SNU Hospital Team Suggests Blood Test Could Identify High-Risk Gastric Cancer Patients Early

2025.05.26

Bladder Cancer Prone to Recurrence Can Now Be Monitored Through Genetic Testing

2025.05.20